Several Methods for Early Diagnosis of Alzheimer’s Disease Developed

ScienceDaily (June 15, 2011) — PredictAD is an EU-funded research project that develops objective and efficient methods for enabling earlier diagnosis of Alzheimer’s disease. Diagnosis requires a holistic view of the patient combining information from several sources, such as, clinical tests, imaging and blood samples.

“The aim of the PredictAD project is to develop an objective indicator to diagnose Alzheimer’s disease at the earliest stage possible. Current diagnostic guidelines emphasise the importance of various biomarkers in diagnostics. We have developed novel approaches to extract biomarkers from imaging data, electrophysiological data and blood samples, and a unique and clinically useful software tool for integrating all these heterogeneous measurements.” says the Scientific Coordinator of the project, Dr Jyrki Lötjönen from VTT Technical Research Centre of Finland.

Magnetic resonance imaging for identifying atrophy

 

Atrophy in the mediotemporal lobe is a well-known hallmark of Alzheimer’s disease. Magnetic resonance imaging is an excellent tool for measuring this tissue loss. In current clinical practice, images are interpreted mostly only by visual inspection but there is a great need for objective measurements.

PredictAD has developed several methods to meet this need. “We have managed to develop efficient tools for measuring the size of the hippocampus, the atrophy rate of the hippocampus, and two modern approaches based on comparing patient data with previously diagnosed cases available in large databases.” says the leader of the imaging biomarkers work-package, professor Daniel Rueckert from Imperial College London. Positron emission tomography (PET) imaging is another imaging technology studied in the project. A novel tracer developed recently especially for diagnostics of Alzheimer’s disease provides promises for very early diagnosis of the disease.

Detecting changes in the electrophysiology of the brain

 

Alzheimer’s disease is known to affect the electromagnetic activity of the brain. In PredictAD, we have studied the performance of a novel technology, transcranial magnetic stimulation (TMS) combined with electroencephalographic (EEG) measures in detecting the disease. The strength of TMS/EEG is that it allows direct and non-invasive perturbation of the human cerebral cortex without requiring the subject’s collaboration. Our study has shown significant changes in Alzheimer’s patients compared with healthy aging people.

Non-invasive techniques to find biomarkers of the disease

 

Molecular level biomarkers are currently under extensive studies in Alzheimer’s research. Many biomarkers, such as tau proteins and b-amyloid 42, measured from the cerebrospinal fluid (CSF), the liquid surrounding the cerebral cortex, have been found to be strongly related with the disease. One major challenge of these biomarkers is that taking samples from CSF is an invasive measurement limiting their usability in early diagnostics. Blood samples would be an excellent source for detecting Alzheimer’s disease as blood sampling is not considered an invasive technique. PredictAD has studied the role of metabolomic and protein compounds in Alzheimer’s disease from blood samples. The preliminary results reveal several promising compounds.

Methodology for measuring the state of the patient

 

Currently, clinicians make the final diagnosis by combining heterogeneous measurements with information from interviews of the patient and relatives. This process involves subjective reasoning and requires strong expertise from the clinicians. Modern hospitals have huge data reserves containing hidden information that could be utilised in diagnostics by systematic mathematical modelling.

PredictAD has designed a totally novel approach for measuring objectively the state of the patient. This decision support system, developed in close collaboration with clinicians, compares patient measurements with measurements of other patients in large databases and provides at the end an index and graphical representation reflecting the state of the patient. “The PredictAD tool provides a new option to support decision making,” says Prof. Hilkka Soininen from the University of Eastern Finland, leading the clinical validation of the project.

Possibilities for significant savings in health costs

 

Prof. Gunhild Waldemar from Copenhagen University Hospital, Rigshospitalet emphasises the importance of the Alzheimer’s disease research: “Successful, early diagnostics combined with the novel drugs under development and early psychosocial care may delay the institutionalisation of patients, reducing suffering and the costs to the society. It has been calculated that delaying the onset of the disease by five years would halve all costs of Alzheimer’s disease and delaying onset and progression by only one year would reduce the number of Alzheimer’s cases by about 10%.”

Read more http://www.sciencedaily.com/releases/2011/06/110615062000.htm

Share

Posted: June 16th, 2011 under Uncategorized.

RSS Medical Imaging News

  • Customizing chemotherapy in lung cancer: New phase II data reported September 27, 2014
    Measuring the expression levels of an enzyme involved in DNA synthesis can help predict the response of lung cancers to certain treatments, a Korean study has shown. In a randomized phase II study, researchers showed that patients whose lung cancers expressed low levels of an enzyme called thymidylate synthase experienced a greater benefit from treatment wit […]
  • Cryptogenic strokes may find explanation in heart September 25, 2014
    More than half of the patients who have suffered a stroke with no well-defined aetiology have an enlarged left atrial appendage of the heart, according to a study. The results indicate that the enlargement of the left atrial appendage may be an independent risk factor of strokes with cardiac origin.
  • Study questions accuracy of lung cancer screens with FDG-PET technology in some geographic regions September 23, 2014
    FDG-PET technology is less accurate in diagnosing lung cancer versus benign disease in regions where infections like histoplasmosis or tuberculosis are common, a new study suggests. Misdiagnosis of lung lesions suspicious for cancer could lead to unnecessary tests and surgeries for patients, with additional potential complications and mortality.
  • Patients accept false-positives to achieve diagnostic sensitivity September 23, 2014
    Both patients and healthcare professionals believe diagnosis of extracolonic malignancy with screening computed tomography colonography greatly outweighs the potential disadvantages of subsequent radiologic or invasive follow-up tests precipitated by false-positive diagnoses, according to a new study.
  • Fine line between breast cancer, normal tissues September 22, 2014
    A tool has been successfully tested that will help surgeons better distinguish cancerous breast tissue from normal tissue, thereby decreasing the chances for repeat operations. The tool, known as DESI mass spectrometry imaging, works by turning molecules into electrically charged versions of themselves, called ions, so that they can be identified by their ma […]
  • Research on photoacoustics to detect breast cancer September 22, 2014
    Researchers report a new method to detect breast cancer based on photoacoustics, which could become an alternative to mammography or sonogram, they say. One advantage this method has over X-rays is that no type of ionizing radiation is used. This technology exploits the property of ultrasonic wave generation in tissue when it is illuminated with short, high- […]
  • Ultrasound enhancement provides clarity to damaged tendons, ligaments September 19, 2014
    Ultrasound is a safe, affordable and noninvasive way to see internal structures, including the developing fetus. Ultrasound can also “see” other soft tissue — including tendons, which attach muscles to bone, and ligaments, which attach bone to bone. Now one expert is commercializing an ultrasound method to analyze the condition of soft tissue.
  • Better way to track emerging cell therapies using MRIs September 19, 2014
    The first human tests of using a perfluorocarbon (PFC) tracer in combination with non-invasive magnetic resonance imaging to track therapeutic immune cells injected into patients with colorectal cancer have been reported by scientists.
  • Multiple sclerosis drug candidate shows new promise September 19, 2014
    Positive new data have been released on a drug candidate, RPC1063, for relapsing multiple sclerosis. According to the results from a six-month Phase 2 study of 258 multiple sclerosis patients, the drug candidate reduced the annualized relapse rate of participants with multiple sclerosis by up to 53 percent, compared with placebo. The potential therapy also d […]
  • Down Syndrome helps researchers understand Alzheimer's disease September 18, 2014
    The link between a protein typically associated with Alzheimer’s disease and its impact on memory and cognition may not be as clear as once thought, according to a new study. Researchers looked at the role of the brain protein amyloid-beta in adults living with Down syndrome, a genetic condition that leaves people more susceptible to developing Alzheimer’s.

News Items

Links